Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palisade Bio Inc PALI

Healthcare Biotechnology
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD... see more

Recent & Breaking News (NDAQ:PALI)

Neuralstem ALS Trial Investigator And Patient On Sirius XM

PR Newswire May 8, 2013

Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting

PR Newswire April 29, 2013

Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment

PR Newswire April 24, 2013

FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder

PR Newswire April 22, 2013

InvestorsGuru.com 41 Filtered Mid-Day Market Movers Recap

Investors Guru April 21, 2013

Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention

PR Newswire April 18, 2013

Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis

PR Newswire April 17, 2013

Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis

PR Newswire April 5, 2013

Neuralstem Secures $8 Million In Debt Financing From Hercules

PR Newswire March 25, 2013

Neuralstem President and CEO, Richard Garr Publishes New Blog Post Titled ''The Best Thing About the Future is that It Comes One Day at a Time''

Accesswire March 20, 2013

Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update

PR Newswire March 15, 2013

Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers"

PR Newswire March 14, 2013

Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High

Marketwired March 6, 2013

Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013

PR Newswire February 7, 2013

Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial

PR Newswire January 14, 2013

Mergers and Acquisitions Within the Biotech Industry Expected to Rise in 2013

Marketwired January 11, 2013

Free Research Reports on CORT, CUR, EXM and SVU Issued by the Bedford Report

Marketwired January 7, 2013

Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech Showcase

PR Newswire January 4, 2013